Welcome to the Second Quarter 2020 Financial Results Conference Call and Webcast for Kindred Biosciences. At this time, all participants have been placed on a listen-only mode. At the end of the prepared statements, participants will have the opportunity to ask questions. Please note that the remarks today will include forward-looking statements and that actual results could differ materially from those projected or implied in our forward-looking statements. For a description of important factors that could cause actual results to differ, we refer you to the forward-looking statements in today’s press release and the note on forward-looking statements in the company’s SEC filings. It is now my pleasure to turn the call over to KindredBio CEO, Richard Chin. Dr. Chin. You may please proceed.

Thank you, Operator. Good afternoon. And welcome to our second quarter 2020 financial results call. Joining me today from the management team of KindredBio are Wendy Wee, our CFO; and Katja Buhrer, our VP of Corporate Development and Investor Relations. Before I start, I would like to thank our Co-Founder, Denise for her incredible contributions to KindredBio. Denise has been instrumental in growing KindredBio into one of the world’s leading veterinary biopharmaceutical companies and I look forward to our ongoing collaboration on the Board, as we continue to realize our vision for this pioneering company we have built together. Thanks to our recent strategic decisions, we are strongly positioned for success. Our focus is on our highest value programs and with the OpEx expected to drop to $10 million per quarter by Q4, we have the crash runway to see us through important milestones and thereby realize the value of our late-stage assets. Turning to our pipeline. We are pleased with our progress in the second quarter. Manufacturing for our IL-31 antibody, which now has the user name, tirnovetmab has been going well and we continue to expect the pivotal study to start this year. Manufacturing scale up is tracking to our expectations. As you know, atopic dermatitis is a very large attractive area. There are couple of approved products that in aggregate sell more than $800 million per year and they are still growing. To put this in perspective, $800 million is a size of a well selling human product, but instead of $1 billion to develop a drug, we can do so for $1,100 of that cost. Now the currently marketed products are excellent drugs, but we think they are vulnerable to competition. Our market research clearly demonstrates that veterinarians are looking for additional options. The current products…

Thanks, Richard. The strategic actions taken in the first half of the year to streamline our operations, reduce expenditures and improved capital efficiency have strengthened our financial position going forward. By prioritizing investment in our highest value late-stage programs, while scaling back our operational footprint, we expect expenses to decrease significantly from their peak this year. As Richard notes, we are on track to reduce our OpEx to approximately $10 million by the fourth quarter and expect this run rate to hold steady next year. With funding through mid-2022, we have both the financial resources and R&D expertise to achieve key development milestones and realize the value of our promising pipeline. Turning to our financial results, variance in key quarterly metrics most notably reflects the completion of the sale of Mirataz to Dechra in April and receipt of associated proceeds. We reported net income of $24 million or $0.60 per share in the second quarter, as compared to a net loss of $14.3 million or $0.37 per share for the same quarter of 2019. For the six months ended June 30th, net income was $1.3 million versus a net loss of $30.4 million in the year ago period. Net revenues were 39.6 and $40.2 million in the three-month and six-month periods, of which $38.7 million relates to the sale of Mirataz. In the respective 2019 timeframe, net revenues were 1.2 and $1.8 million. Royalty revenue totaled $158,000 in the quarter. We are pleased to see the growing demand for Mirataz doing its first partial quarter in the hands of Dechra. Substantially all first half product revenues related to Mirataz with $138,000 earned in the second quarter. Following completion of the transaction, future global sales by Dechra will be recorded by KindredBio as royalty revenue. Zimeta product revenues were $7,000 in…

Thank you, Wendy. Operator, we are ready for questions.

Thank you. [Operator Instructions] We have a question from Jon Block from Stifel.

Great. Thanks, guys. Good afternoon. Richard, sort of a high level or broad based question, but I am just curious, when you see the market data shows that veterinarians are looking for options for atopic derm. What are they looking for, maybe you can just help us out and be more specific there, is it a cheaper option, are they looking for better duration, is it a greater efficacy? What do you think the greatest unmet need in the marketplace is today for atopic derm?

Absolutely. So we have done a fair amount of market research in that field and the two things that stand out our efficacy and duration of effect. So with regard to efficacy, there are fair number of animals that don’t respond to current therapies or they lose their response to the current therapies after a period of time. In addition, there are quite a few animals that don’t respond completely. So the veterinarians are sometimes using both of the current product together or the current product together with cyclosporine. So that’s number one and tied into that, of course, is a desire to have better efficacy on the disease itself as opposed to the symptoms. So the current therapies are good, but there is quite a bit of room for additional product. With duration of effect, from our data, it appears that once a month dosing is an advantage over daily dosing. But beyond that, if the dosing could be after two months or three months, there is very strong preference for that product profile compared to what’s currently available.

Got it. Great. And that’s actually a good segue I will some around my order into Half-Life technology and move to mAbs. For Half-Life technology, can you remind us of the clinical pathway? In other words, when some of the mAbs are approved, do you need to go back and run a new clinical from start call it in order to get the Half-Life technology out there and commercialize?

Yes. It’s a new drug. So the pivotal study will have to be re-run. The pilot study, we won’t have to repeat all the pilot studies because the part that binds to the target is unchanged. So we expect that the program will move more quickly, but we will have to submit a full package.

Great. That was very helpful. Maybe the last one for me, just the timing of the 016 partnership, I think you sort of hinted at it before that you are more likely to wait. But just to sort of walk through a timeline of the trials enrollments initiated in the fourth quarter of this year, like, you alluded to. It seems like you have been more comfortable with the 12-month timeline for atopic derm just because of the demand maybe you want to sign off on that. Just walk us through the timeline, do we get data, call it, in 1H ‘22 and is that when we should start to think about some of the partnerships being formed for the drug? Thanks guys.

Yes. So under normal circumstances, if we start the study end of this year, we would expect to read out end of next year and then the approval would come the following year. The COVID-19 pandemic has put in a new variable that’s hard to predict. So we know there is going to be some effect on enrollment. We don’t know how much. It really depends on the severity. So under ideal circumstances, about a year to do the study and another six months to 12 months from end of efficacy study till approval, but we are leaving that sort of open-ended right now until we see where that COVID-19 pandemic goes.

Okay. And I am sorry, if I can just tack on the last part of the third question, but Richard any partnerships would likely come between those two, right? When you talk about the readout…

Oh! Yes. I am sorry. Yeah.

Okay.

Yeah. That’s right.

That’s right. Okay.

That in measure, I said that part [ph]. Yes. The ideal time to partner would be after the positive readout and launch, because we would want to prepare for the launch, obviously, yes. So that would be the idea. And by then almost all the risk is removed, so we will be in a position to capture most of the potential value.

Understood. Thanks. Appreciate it. I will follow-up offline.

Sure.

Thank you. The next question comes from Balaji Prasad from Barclays.

Hi. Thanks for taking my question, Richard. Probably just to start with on the parvovirus mAb, so you mentioned that you are conducting pivotal studies now and which are expected to be completed by end of 2020 and approval early 2021. So can you help by what the timeline is going to look like from the time of completion of the study to the filing to the review and review and then approval? And secondly, so I expect that there are other pivotal study studies being conducted too, right? Could you just help us this time the nature of these studies and what would this mean for approvals? Thanks.

So I am assuming you are talking about with the second part of that question, I assume you are talking about the parvovirus pivotal?

Absolutely. Yeah.

Okay. That’s right. Yeah. That’s right. So the pivotal studies for this program are fast because they are laboratory studies. The USDA has been working with us and have been very accommodating because this is such a huge unmet medical need. So the pivotal studies should be finished within the next couple of months, give or take and then we will file pretty much immediately after that. So there is some variability in the regulatory timeline, because USDA doesn’t have the equivalent to PDUFA. So the timelines that we are using are basically the typical timeline for review and based on that we think that the review should be complete by early next year, so the readout this year and then approval early next year. Does that answer your question?

Yeah. And the second part was, like, there will be other pure study is being conducted in this, right? So how would this impact…

Yeah.

…the application -- the approval?

So when I said I -- we are in the midst of pivotal studies, I mean, that we are in the middle of doing the pivotal studies right now. So we are completing one of them and then we have some additional work that we have planned.

Got it.

So all the pivotal will readout this year.

Understood. And maybe second question is on, probably, the revenue nature. So we saw that you booked some royalty revenues of around $0.5 million -- $150,000 this quarter and you had some $0.5 million from Vaxart -- from the Dechra Vaxart. Setting these aside considering that you have two large biologics facilities -- have two dedicated biologic facility, is there a potential for any large contract manufacturing deal in size and scale compared to what you have currently?

Yeah. So there is definitely potential for that, but we don’t want to commit to that at this point. There are some large companies that are interested in our manufacturing capacity and especially with the COVID pandemic there is increased demand for manufacturing capacity. So that is a -- that is something that we are pursuing, but we are not at a point where we can predict with certainty that will materialize.

Understood. Thanks, Richard

Thank you. Our next question comes from Brandon Folkes from Cantor Fitzgerald.

Hi. Thanks for taking my questions and congratulations on all the progress in the quarter. And firstly, maybe Richard, can you just talk a little bit about what do you think the market is missing with your stock? And then as we look ahead towards the upcoming data readout and where do you think you have the most significant opportunity to really drive investors to better appreciate the value in your pipeline? And then, secondly, I think, we have seen a lot of large scale M&A in animal health recently, it sounds like you are not seeking partnerships in the near-term. But maybe just -- can you just comment whether you continue to the interest in the near-term as well? And then, lastly, can you provide any color on Mirataz’s performance in the hands of Dechra and whether they have launched in the EU and how the product is doing there? Thank you.

Yeah. Sure, Absolutely. So we think there is a tremendous amount of value in our pipeline. So if you look at even one of our atopic dermatitis products, each one of those dermatitis products has the potential to be a blockbuster and blockbuster can be anywhere from $100 million to a $1 billion, we know that the atopic dermatitis market is very large and there is room for a product that could become the market leader, so even one of those products is worth quite a bit. Now, obviously, that’s not reflected in our stock price right now. Our stock is volatile if you know. So if you look in the past, there have been periods where the value has been not -- has not been reflected in the stock price but it’s always come back and we are confident that will happen. The pipeline in lot of the other veterinary pharmaceutical companies are skew towards livestock and vaccines and there is paucity of really promising products for the companion animal sector. And as we talk to the partners, not just about the atopic dermatitis products, but some of the other products, there is a lot of interest in the other products as well. So, obviously, we wouldn’t comment on M&A. But what I can say is, there is lot of interest and in some cases a need for some of the products that are in our pipeline. With regard to Mirataz, we don’t have complete visibility into the specifics, because obviously, it’s in the hands of our partner. However, the feedback we are getting is that it’s going very well. They have not launched in EU yet, but they expect that to happen shortly. So the transition was smooth. We are happy with it. They are happy with it. They are happy with how the product is being received. Does I answered all of your questions, Brandon?

I will believe those were his questions. I will go to the next question.

Okay. Go ahead. Yeah.

From David Westenberg from Guggenheim Securities.

Hi. Thanks for taking my question. So I want to actually keep going with that topic. Is there any change to maybe peak sales or thoughts of peak sales in Mirataz, I mean, I do believe the Dechra has a larger sales force and then would also be as Brandon alluded to in more than one more or in more than a bigger presence than in just the U.S.?

So I am not sure the peak sales will change, but I think what will change is the speed of uptake. So we believe that with Dechra sales force, which is large and also very, very well regarded. We think the sales numbers will climb and will hit the peak sales earlier than we otherwise would have.

Great. Thank you. Thank you. And then just a quick housekeeping question for Wendy. In terms of our -- right now I was kind of modeling R&D to stay fairly the same for this quarter and then the G&A part to really be the one that gets us to that $40 million. Is the run rate this quarter in R&D kind of what we should see for the next few quarters or is there even maybe some decrease there, just in the -- as we update our models over the next couple of quarters? Thank you.

Sure. The run rate for R&D, we will see a slight uptick in the third quarter because of the parvo pivotal study. But in general, it will remain in the same expense level for the remainder of the year, obviously G&A -- SG&A expenses will be lower.

I appreciate it. Thank you for taking my questions.

Sure.

Thank you. Our next question comes from Ben Haynor from Alliance Global Partners.

Good afternoon, guys. Thanks for taking the questions. First off from me, just assuming that the anti-TNF antibody pilot goes well, how quickly do you think you could move into a pivotal there and then what would the follow-up period look like on a pivotal at least as it’s envision now?

So the pivotal will be gated by manufacturing and so there will be like a few months at least. What we probably would do is once we have the positive study try to find a partner, because we are focused on keeping our OpEx down. We believe that if we have positive results there will be a lot of interest in this product from our potential partners. So I don’t think at this point, we would want to layout a timeline for that. But once the study has started, we expect the timelines would be similar to atopic dermatitis, because it’s a fairly common disease.

Got it. And then just because you had suspended the trial for epoCat with COVID, is -- and this may be a long shot, but I figured, I’d ask anyway. Do you guys give any kind of anecdotal feedback on the cats that may have gone without epoCat for multiple months and are there any, I guess, protocol deviations that you might be able to almost use in some fashion or is that just not?

I have not heard that we had a lot of protocol deviation. So I don’t think there is anything extraordinary or else I would have heard about it.

Okay. Fair enough. And then, lastly from me, you mentioned that, you have a term sheet signed for the equine assets. When do you expect that to close and then will there be any savings from maybe some employees going over to the buyer or it doesn’t that factor in?

Yeah. There will definitely be savings and that’s independent of whether the buyer, it takes on some of our employees, simply because we won’t have to maintain the infrastructure we need to support a marketed product. So it will lower the OpEx once that closes. The -- we are working on the definitive agreement right now. So it will take few weeks for that to be finalized and then the closing of the transaction probably take several weeks after that.

So it could slip into Q4 potentially?

Yeah. Potentially. Yes.

Okay. Great. That’s all I have. Thanks a lot for taking the questions guys.

Thanks, Ben.

Thank you. We have a question from RK from H.C. Wainwright. Please go ahead.

Thank you. Good afternoon, Richard and Wendy. Couple of quick questions, parvovirus, as I believe is an issue, mostly seen during the early stages of life of a dog. Do you need to look for specialized sales force or partners for interest who have a certain sales force that can reach out to the breeders and shelters, so do you think that could -- will that -- is that a concern or is that an issue when you go to partner this product out?

So the parvovirus cases do typically occur when the dogs are young and you are absolutely right that breeders see a lot of it and so do shelters. But there are also seen in general medicine, because even for vaccinated animals and not all animals are vaccinated, but even from the ones that are vaccinated, there is a window of vulnerability before the vaccines kick in. So if during that period vulnerability the -- if the puppy comes in contact with another puppy that’s infected or in contact with, let’s say, some surface, road or furniture or tree, that has been in contact with an infected animal in the past several days then they can contracted. So you see epidemics of parvovirus in the community as well. Most of the partners that we are talking to about parvovirus have large sales forces and they do have reach into shelters and breeders, so we do need to cover those markets, but most of the companies we are talking with can do that.

Okay. Thank you. And then for the epoCat, what’s the timeline for this program and what sort of interest are you seeing again in the marketplace?

Yeah. So the timeline for this is fairly long, because this is a disease that has to be diagnosed with lab. So alike atopic dermatitis where the disease is very apparent, we have to screen for these animals and that, obviously, makes the enrollment slower. But in addition, because we are prioritizing our resources towards the atopic dermatitis products, we think this product enrollment will take quite a while. And there’s definitely interest from potential partners. It’s a significant unmet medical need and there are several companies that are doing due diligence on the product right now. Having said that, the size of the market is more difficult to estimate than the size of, let’s say, the atopic dermatitis market. So we may partner this earlier or later in the development in this -- in terms of when in development we partner. As we get more clarity on the time to approval in a better position to give you an update.

Thank you, Richard. Thanks for taking all my questions

Sure.

Thank you. [Operator Instructions] Our next question comes from Nathan Weinstein from Aegis Capital.

Hi, guys. Thanks for taking my question. So if I could just ask one big picture question and we have long talked about animal health as the recessionary resistant market and we are in the midst of sort of an unprecedented time with COVID. If you could just comment on what you are seeing, how resilient is the market now in the midst of this pandemic? Thank you.

Yeah. The market is very resilient. It’s one of the few sectors of the economy that had a clear V-shaped response. So the clinic visits did drop during the shutdown. But as soon as the restrictions were loosened, the clinic visits shot right back up. And on top of that there are a lot of families that are getting new pets. So not only is it recession resistant, but it is a growth sector during recession -- during -- well, not during recession, but during periods where people can’t go outside of the house for entertainment.

Thank you.

Thank you. And there are no further questions at this time. I would like to turn the call back to Dr. Richard Chin, CEO for any further remarks.

Thank you, Operator. I’d like to thank our listeners for your support as we continue to advance our product and a promising pipeline. We have an exciting future ahead of us.

Thank you, ladies and gentlemen. This concludes today’s conference. Thank you for participating. You may now disconnect.